Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

er-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys and Copegus are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 26, 2011 Galleon Pharmaceuticals, a leader in the ... board of directors has elected Thomas J. Dietz, Ph.D., ... CEO of Waypoint Holdings, LLC, a diversified financial-holdings and ... was co-CEO and then CEO and a director of ...
... Oct. 26, 2011 Reportlinker.com announces that ... in its catalogue: Wheelchair ... to 2015 http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... 484 pages, 235 tables and figures. Worldwide ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... care to properly heal , ... ... On the one-year anniversary of the massive earthquake that devastated ... education and humanitarian assistance organization, is officially launching the China ...
... Health Organization urge vigilance against the "swine flu" (Type A influenza ... Huff, recommends practical tips for protecting your young child and baby ... ... Asheville, NC (PRWEB) May 12, 2009 -- The World Health Organization ...
... Chairman of the,Avon Foundation for Women, today joined ... Women leaders for a day of events to ... Breast Center at the San,Francisco General Hospital and ... making progress possible in breast cancer research and,care. ...
... Tenn., May 11 Brookdale Senior Living Inc. (NYSE: ... Executive Officer, and Mark Ohlendorf, Co-President and Chief Financial Officer, ... of America and Merrill Lynch 2009 Health Care Conference in ... 10:00 a.m. Eastern Time.The presentation is being audio webcast live ...
... Entity for Topical Acne Treatment in a DecadeCARLSBAD, Calif., May ... entered into a co-promotion agreement with Allergan for ACZONE(R) ... Representing the first new molecule in a decade approved by ... 12 years of age and older, ACZONE(R) Gel 5% combines ...
... following statement is from Regence BlueCross BlueShield President and CEO ... by a group of private-sector health industry leaders to decrease ... as much as $2 trillion over the next ten years:"I ... costs in our nation. We are a country that ...
Cached Medicine News:Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 2Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 3Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 2Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 3Health News:MultiVu Video Feed: REESE WITHERSPOON JOINS AVON FOUNDATION FOR WOMEN AND SAN FRANCISCO GENERAL HOSPITAL TO CELEBRATE 5TH ANNIVERSARY OF AVON COMPREHENSIVE BREAST CENTER 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 3Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 4Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: